Compare TTC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTC | BMRN |
|---|---|---|
| Founded | 1914 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tools/Hardware | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.4B |
| IPO Year | 1994 | 1999 |
| Metric | TTC | BMRN |
|---|---|---|
| Price | $91.02 | $53.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 18 |
| Target Price | ★ $104.00 | $88.22 |
| AVG Volume (30 Days) | 579.3K | ★ 1.6M |
| Earning Date | 06-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | 0.54 |
| Revenue | ★ $2,618,650,000.00 | $1,313,646,000.00 |
| Revenue This Year | $6.13 | $15.02 |
| Revenue Next Year | $4.45 | $12.23 |
| P/E Ratio | $137.43 | ★ $97.94 |
| Revenue Growth | 4.53 | ★ 17.62 |
| 52 Week Low | $67.45 | $50.76 |
| 52 Week High | $105.19 | $66.28 |
| Indicator | TTC | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 45.23 |
| Support Level | $77.96 | $52.06 |
| Resistance Level | $97.27 | $56.91 |
| Average True Range (ATR) | 2.15 | 1.71 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 15.04 | 26.03 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.